Wikipedia

Dopamine receptor

Dopamine receptorsare a class ofG protein-coupled receptorsthat are prominent in thevertebratecentral nervous system(CNS). Dopamine receptors activate different effectors through not only G-protein coupling, but also signaling through different protein (dopamine receptor-interacting proteins) interactions.[1]Theneurotransmitterdopamineis the primaryendogenousligandfor dopamine receptors.

Dopamine

Dopamine receptors are implicated in many neurological processes, including motivational and incentive salience, cognition, memory, learning, and fine motor control, as well as modulation ofneuroendocrinesignaling. Abnormal dopamine receptor signaling and dopaminergic nerve function is implicated in several neuropsychiatric disorders.[2]Thus, dopamine receptors are common neurologic drug targets;antipsychoticsare often dopaminereceptor antagonistswhilepsychostimulantsare typicallyindirect agonistsof dopamine receptors.

Subtypes

edit

The existence of multiple types of receptors for dopamine was first proposed in 1976.[3][4]There are at least five subtypes of dopamine receptors, D1,D2,D3,D4,and D5.The D1and D5receptors are members of theD1-like familyof dopamine receptors, whereas the D2,D3and D4receptors are members of theD2-like family.There is also some evidence that suggests the existence of possible D6and D7dopamine receptors, but such receptors have not been conclusively identified.[5]

At a global level, D1receptors have widespread expression throughout the brain. The relative amount of DA receptors is in the following order: D1 > D2 > D3 > D5 > D4.[6]D1-2receptor subtypes are found at 10–100 times the levels of the D3-5subtypes.[7]

D1-like family

edit

TheD1-like family receptorsare coupled to theG proteinGsα.D1is also coupled toGolf.

Gsαsubsequently activatesadenylyl cyclase,increasing the intracellular concentration of thesecond messengercyclic adenosine monophosphate(cAMP).[8]

D2-like family

edit

TheD2-like family receptorsare coupled to theG proteinGiα,which directly inhibits the formation ofcAMPby inhibiting the enzyme adenylyl cyclase.[9]

Receptor heteromers

edit

Dopamine receptors have been shown to heteromerize with a number of otherG protein-coupled receptors.[16]Especially the D2 receptor is considered a major hub within theGPCR heteromernetwork.[17]Protomersconsist of

Isoreceptors[18]

  • D1–D2
  • D1–D3
  • D2–D3
  • D2–D4
  • D2–D5

Non-isoreceptors

Signaling mechanism

edit

Dopamine receptor D1andDopamine receptor D5areGscoupled receptors that stimulateadenylyl cyclaseto producecAMP,which in turn increases intracellular calcium and mediates a number of other functions. The D2 class of receptors produce the opposite effect, as they areGαiand/orGαocoupled receptors, which blocks the activity of adenylyl cyclase. cAMP mediatedprotein kinase Aactivity also results in the phosphorylation ofDARPP-32,an inhibitor ofprotein phosphatase 1.Sustained D1 receptor activity is kept in check byCyclin-dependent kinase 5.Dopamine receptor activation ofCa2+/calmodulin-dependent protein kinase IIcan be cAMP dependent or independent.[19]

The cAMP mediated pathway results in amplification of PKA phosphorylation activity, which is normally kept in equilibrium by PP1. The DARPP-32 mediated PP1 inhibition amplifies PKA phosphorylation of AMPA, NMDA, and inward rectifying potassium channels, increasing AMPA and NMDA currents while decreasing potassium conductance.[8]

cAMP independent

edit

D1 receptor agonism and D2 receptor blockade also increases mRNA translation by phosphorylatingribosomal protein s6,resulting in activation of mTOR. The behavioral implications are unknown. Dopamine receptors may also regulateion channelsandBDNFindependent of cAMP, possibly through direct interactions. There is evidence that D1 receptor agonism regulatesphospholipase Cindependent of cAMP, however implications and mechanisms remain poorly understood. D2 receptor signaling may mediateprotein kinase B,arrestin beta 2,andGSK-3activity, and inhibition of these proteins results in stunting of the hyperlocomotion inamphetaminetreated rats. Dopamine receptors can also transactivateReceptor tyrosine kinases.[19]

Beta Arrestin recruitment is mediated by G-protein kinases that phosphorylate and inactivate dopamine receptors after stimulation. While beta arrestin plays a role in receptor desensitization, it may also be critical in mediating downstream effects of dopamine receptors. Beta arrestin has been shown to form complexes with MAP kinase, leading to activation ofextracellular signal-regulated kinases.Furthermore, this pathway has been demonstrated to be involved in the locomotor response mediated by dopamine receptor D1. Dopamine receptor D2 stimulation results in the formation of an Akt/Beta-arrestin/PP2Aprotein complex that inhibits Akt through PP2A phosphorylation, therefore disinhibiting GSK-3.[20]

Role in the central nervous system

edit
Further information:Neurotransmitter § Brain neurotransmitter systems
Further information:Dopaminergic pathways

Dopamine receptors control neural signaling that modulates many important behaviors, such asspatialworking memory.[21]Dopamine also plays an important role in thereward system,incentive salience,cognition,prolactinrelease,emesisand motor function.[22]

Non-CNS dopamine receptors

edit

Cardio-pulmonary system

edit

In humans, thepulmonary arteryexpresses D1,D2,D4,and D5and receptor subtypes, which may account forvasodilatoryeffects of dopamine in the blood.[23]Such receptor subtypes have also been discovered in theepicardium,myocardium,andendocardiumof the heart.[24]Inrats,D1-like receptors are present on thesmooth muscleof theblood vesselsin most major organs.[25]

D4receptors have been identified in theatriaof rat and humanhearts.[26]Dopamine increasesmyocardialcontractility andcardiac output,without changingheart rate,by signaling through dopamine receptors.[5]

Renal system

edit

Dopamine receptors are present along thenephronin thekidney,withproximal tubuleepithelial cellsshowing the highest density.[25]Inrats,D1-like receptors are present on thejuxtaglomerular apparatusand onrenal tubules,while D2-like receptors are present on theglomeruli,zona glomerulosacells of the adrenal cortex, renal tubules, and postganglionicsympathetic nerveterminals.[25]Dopamine signaling affectsdiuresisandnatriuresis.[5]

The Pancreas

edit

The role of the pancreas[27]is to secretedigestive enzymesviaexocrine glandsandhormonesviaendocrine glands.Pancreatic endocrine glands, composed of dense clusters of cells called theIslets of Langerhans,secreteinsulin,glucagon,andother hormonesessential for metabolism andglycemic control.Insulin secreting beta cells have been intensely researched due to their role indiabetes.[28]

Recent studies have found thatbeta cells,as well as other endocrine and exocrine pancreatic cells, express D2 receptors[29]and that beta cells co-secrete dopamine along with insulin.[30]Dopamine has been purported to be a negative regulator of insulin,[31][32]meaning that bound D2 receptors inhibit insulin secretion. The connection between dopamine and beta cells was discovered, in part, due to the metabolic side-effects of certainantipsychotic medications.[33][34]Traditional/typical antipsychotic medicationsfunction by altering the dopamine pathway in the brain, such as blocking D2 receptors.[35]Common side effects of these medications include rapid weight gain and glycemic dysregulation, among others.[36]The effects of these medications are not limited to the brain, so off-target effects in other organs such as the pancreas have been proposed as a possible mechanism.[37]

In disease

edit

Dysfunction of dopaminergic neurotransmission in the CNS has been implicated in a variety of neuropsychiatric disorders, includingsocial phobia,[38]Tourette's syndrome,[39]Parkinson's disease,[40]schizophrenia,[39]neuroleptic malignant syndrome,[41]attention-deficit hyperactivity disorder(ADHD),[42]anddrugandalcoholdependence.[39][43]

Attention-deficit hyperactivity disorder

edit
Main article:Attention-deficit hyperactivity disorder

Dopamine receptors have been recognized as important components in the mechanism of ADHD for many years. Drugs used to treat ADHD, includingmethylphenidateandamphetamine,have significant effects on neuronal dopamine signaling. Studies ofgene associationhave implicated several genes within dopamine signaling pathways; in particular, the D4.7variant of D4has been consistently shown to be more frequent in ADHD patients.[44]ADHD patients with the 4.7 allele also tend to have better cognitive performance and long-term outcomes compared to ADHD patients without the 4.7 allele, suggesting that the allele is associated with a more benign form of ADHD.[44]

The D4.7allele has suppressedgene expressioncompared to other variants.[45]

Addictive drugs

edit
Main article:Addiction

Dopamine is the primary neurotransmitter involved in thereward and reinforcement (mesolimbic) pathwayin the brain. Although it was a long-held belief that dopamine was the cause of pleasurable sensations such as euphoria, many studies and experiments on the subject have demonstrated that this is not the case; rather, dopamine in the mesolimbic pathway is responsible for behaviour reinforcement ( "wanting" ) without producing any "liking" sensation on its own.[46][47][48][49]Mesolimbic dopamine and its related receptors are a primary mechanism through which drug-seeking behaviour develops (Incentive Salience), and manyrecreational drugs,such ascocaineandsubstituted amphetamines,inhibit thedopamine transporter(DAT), the protein responsible for removing dopamine from the neuralsynapse.When DAT activity is blocked, the synapse floods with dopamine and increases dopaminergic signaling. When this occurs, particularly in thenucleus accumbens,[50]increased D1[43]and decreased D2[50]receptor signaling mediates the "incentive salience" factor and can significantly increase positive associations with the drug in the brain.[49]

Pathological gambling

edit
Main article:Problem gambling

Pathological gambling is classified as a mental health disorder that has been linked to obsessive-compulsive spectrum disorder and behavioral addiction. Dopamine has been associated with reward and reinforcement in relation to behaviors and drug addiction.[51]The role between dopamine and pathological gambling may be a link between cerebrospinal fluid measures of dopamine and dopamine metabolites in pathological gambling.[52]Molecular genetic study shows that pathological gambling is associated with the TaqA1 allele of the Dopamine Receptor D2 (DRD2) dopamine receptor. Furthermore, TaqA1 allele is associated with other reward and reinforcement disorders, such as substance abuse and other psychiatric disorders. Reviews of these studies suggest that pathological gambling and dopamine are linked; however, the studies that succeed in controlling for race or ethnicity, and obtain DSM-IV diagnoses do not show a relationship between TaqA1 allelic frequencies and the diagnostic of pathological gambling.[51]

Schizophrenia

edit
Main article:Dopamine hypothesis of schizophrenia

While there is evidence that the dopamine system is involved inschizophrenia,the theory that hyperactive dopaminergicsignal transductioninduces the disease is controversial. Psychostimulants, such as amphetamine and cocaine, indirectly increase dopamine signaling; large doses and prolonged use can induce symptoms that resemble schizophrenia. Additionally, manyantipsychoticdrugs target dopamine receptors, especially D2receptors.

Genetic hypertension

edit

Dopamine receptormutationscan cause genetichypertensionin humans.[53]This can occur inanimal modelsand humans with defective dopamine receptor activity, particularly D1.[25]

Parkinson's disease

edit

Parkinson's disease is associated with the loss of cells responsible for dopamine synthesis and other neurodegenerative events.[51]Parkinson's disease patients are treated with medications which help to replenish dopamine availability, allowing relatively normal brain function and neurotransmission.[54]Research shows that Parkinson's disease is linked to the class of dopamine agonists instead of specific agents. Reviews touch upon the need to control and regulate dopamine doses for Parkinson's patients with a history of addiction, and those with variable tolerance or sensitivity to dopamine.[55]

Dopamine regulation

edit
See also:Yerkes–Dodson law

Dopamine receptors are typically stable, however sharp (and sometimes prolonged) increases or decreases in dopamine levels candownregulate(reduce the numbers of) orupregulate(increase the numbers of) dopamine receptors.[56]

Haloperidol,and some other antipsychotics, have been shown to increase the binding capacity of the D2receptor when used over long periods of time (i.e. increasing the number of such receptors).[57]Haloperidol increased the number of binding sites by 98% above baseline in the worst cases, and yielded significant dyskinesia side effects.

Addictive stimulihave variable effects on dopamine receptors, depending on the particular stimulus.[58]According to one study,[59]cocaine,opioidslikeheroin,amphetamine, alcohol, andnicotinecause decreases in D2receptor quantity. A similar association has been linked to food addiction, with a low availability of dopamine receptors present in people with greater food intake.[60][61]A recent news article[62]summarized a U.S.DOEBrookhaven National Laboratory study showing that increasing dopamine receptors with genetic therapy temporarily decreased cocaine consumption by up to 75%. The treatment was effective for 6 days. Cocaine upregulates D3receptors in thenucleus accumbens,further reinforcing drug seeking behavior.[63]andCaffeineincreases striatal dopamine D2/D3receptor availability in the human brain,[64]Caffeine, or other more selectiveadenosine A2A receptorantagonists, causes significantly less motor stimulation in dopamine D2receptor.[65]

Certain stimulants will enhance cognition in the general population (e.g., direct or indirectmesocorticalDRD1agonists as a class), but only when used at low (therapeutic) concentrations.[66][67][68]Relatively high doses of dopaminergic stimulants will result in cognitive deficits.[67][68]

Summary of addiction-related plasticity
Form ofneuroplasticity
orbehavioral plasticity 		Type ofreinforcer Sources
Opiates Psychostimulants High fat or sugar food Sexual intercourse Physical exercise
(aerobic) 		Environmental
enrichment
ΔFosBexpression in
nucleus accumbensD1-typeMSNsTooltip medium spiny neurons 		↑ ↑ ↑ ↑ ↑ ↑ [58]
Behavioral plasticity
Escalation of intake Yes Yes Yes [58]
Psychostimulant
cross-sensitization 		Yes Not applicable Yes Yes Attenuated Attenuated [58]
Psychostimulant
self-administration 		↑ ↑ ↓ ↓ ↓ [58]
Psychostimulant
conditioned place preference 		↑ ↑ ↓ ↑ ↓ ↑ [58]
Reinstatement of drug-seeking behavior ↑ ↑ ↓ ↓ [58]
Neurochemical plasticity
CREBTooltip cAMP response element-binding proteinphosphorylation
in thenucleus accumbens 		↓ ↓ ↓ ↓ ↓ [58]
Sensitizeddopamineresponse
in thenucleus accumbens 		No Yes No Yes [58]
Alteredstriataldopamine signaling ↓DRD2,↑DRD3 ↑DRD1,↓DRD2,↑DRD3 ↑DRD1,↓DRD2,↑DRD3 ↑DRD2 ↑DRD2 [58]
Altered striatalopioid signaling No change or
↑μ-opioid receptors		 ↑μ-opioid receptors
↑κ-opioid receptors		 ↑μ-opioid receptors ↑μ-opioid receptors No change No change [58]
Changes in striatalopioid peptides ↑dynorphin
No change:enkephalin		 ↑dynorphin ↓enkephalin ↑dynorphin ↑dynorphin [58]
Mesocorticolimbicsynaptic plasticity
Number ofdendritesin thenucleus accumbens ↓ ↑ ↑ [58]
Dendritic spinedensity in
thenucleus accumbens 		↓ ↑ ↑ [58]

See also

edit

References

edit
  1. ^Rondou P, Haegeman G, Van Craenenbroeck K (June 2010)."The dopamine D4 receptor: biochemical and signalling properties".Cellular and Molecular Life Sciences.67(12):1971–86.doi:10.1007/s00018-010-0293-y.PMC11115718.PMID20165900.S2CID21432517.
  2. ^Girault JA, Greengard P (2004). "The neurobiology of dopamine signaling".Arch. Neurol.61(5):641–4.doi:10.1001/archneur.61.5.641.PMID15148138.
  3. ^Cools AR,Van Rossum JM (1976). "Excitation-mediating and inhibition-mediating dopamine-receptors: a new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data".Psychopharmacologia.45(3):243–254.doi:10.1007/bf00421135.PMID175391.S2CID40366909.
  4. ^Ellenbroek BA, Homberg J, Verheij M, Spooren W, van den Bos R, Martens G (2014)."Alexander Rudolf Cools (1942-2013)".Psychopharmacology.231(11):2219–2222.doi:10.1007/s00213-014-3583-5.PMID24770629.
  5. ^abcContreras F, Fouillioux C, Bolívar A, Simonovis N, Hernández-Hernández R, Armas-Hernandez MJ, et al. (2002). "Dopamine, hypertension and obesity".J Hum Hypertens.16(Suppl 1): S13–7.doi:10.1038/sj.jhh.1001334.PMID11986886.
  6. ^Mishra A, Singh S, Shukla S (1 January 2018)."Physiological and Functional Basis of Dopamine Receptors and Their Role in Neurogenesis: Possible Implication for Parkinson's disease".Journal of Experimental Neuroscience.12.doi:10.1177/1179069518779829.ISSN1179-0695.PMC5985548.PMID29899667.
  7. ^Hurley MJ, Jenner P (2006). "What has been learnt from study of dopamine receptors in Parkinson's disease?".Pharmacol. Ther.111(3):715–28.doi:10.1016/j.pharmthera.2005.12.001.PMID16458973.
  8. ^abNeve KA, Seamans JK, Trantham-Davidson H (August 2004)."Dopamine receptor signaling".Journal of Receptor and Signal Transduction Research.24(3):165–205.doi:10.1081/RRS-200029981.PMID15521361.S2CID12407397.
  9. ^Neves SR, Ram PT, Iyengar R (2002). "G protein pathways".Science.296(5573):1636–9.Bibcode:2002Sci...296.1636N.doi:10.1126/science.1071550.PMID12040175.S2CID20136388.
  10. ^ab"Introduction to Neuroscience".
  11. ^Suzuki M, Hurd YL, Sokoloff P, Schwartz JC, Sedvall G (1998). "D3 dopamine receptor mRNA is widely expressed in the human brain".Brain Res.779(1–2):58–74.doi:10.1016/S0006-8993(97)01078-0.PMID9473588.S2CID46096849.
  12. ^NCBI Database
  13. ^Manor I, Tyano S, Eisenberg J, Bachner-Melman R, Kotler M, Ebstein RP (2002). "The short DRD4 repeats confer risk to attention deficit hyperactivity disorder in a family-based design and impair performance on a continuous performance test (TOVA)".Mol. Psychiatry.7(7):790–4.doi:10.1038/sj.mp.4001078.PMID12192625.
  14. ^Langley K, Marshall L, van den Bree M, Thomas H, Owen M, O'Donovan M, et al. (2004). "Association of the dopamine D4 receptor gene 7-repeat allele with neuropsychological test performance of children with ADHD".Am J Psychiatry.161(1):133–8.doi:10.1176/appi.ajp.161.1.133.PMID14702261.S2CID25892078.
  15. ^Kustanovich V, Ishii J, Crawford L, Yang M, McGough JJ, McCracken JT, et al. (2004). "Transmission disequilibrium testing of dopamine-related candidate gene polymorphisms in ADHD: confirmation of association of ADHD with DRD4 and DRD5".Mol. Psychiatry.9(7):711–7.doi:10.1038/sj.mp.4001466.PMID14699430.
  16. ^Beaulieu JM, Espinoza S, Gainetdinov RR (2015)."Dopamine receptors – IUPHAR Review 13".Br. J. Pharmacol.172(1):1–23.doi:10.1111/bph.12906.PMC4280963.PMID25671228.
  17. ^Borroto-Escuela DO, Brito I, Romero-Fernandez W, et al. (May 2014)."The G protein-coupled receptor heterodimer network (GPCR-HetNet) and its hub components".Int J Mol Sci.15(5):8570–90.doi:10.3390/ijms15058570.PMC4057749.PMID24830558.
  18. ^Agnati LF, Guidolin D, Cervetto C, Borroto-Escuela DO, Fuxe K (January 2016)."Role of iso-receptors in receptor-receptor interactions with a focus on dopamine iso-receptor complexes".Rev Neurosci.27(1):1–25.doi:10.1515/revneuro-2015-0024.PMID26418645.
  19. ^abBeaulieu JM, Espinoza S, Gainetdinov RR (January 2015)."Dopamine receptors – IUPHAR Review 13".British Journal of Pharmacology.172(1):1–23.doi:10.1111/bph.12906.PMC4280963.PMID25671228.
  20. ^Del'guidice T, Lemasson M, Beaulieu JM (2011)."Role of Beta-arrestin 2 downstream of dopamine receptors in the Basal Ganglia".Frontiers in Neuroanatomy.5:58.doi:10.3389/fnana.2011.00058.PMC3167352.PMID21922001.
  21. ^Williams GV, Castner SA (2006). "Under the curve: critical issues for elucidating D1 receptor function in working memory".Neuroscience.139(1):263–76.doi:10.1016/j.neuroscience.2005.09.028.PMID16310964.S2CID20906770.
  22. ^Webster R (2001).Neurotransmitters, drugs and brain function(Repr. ed.). Chichester: Wiley. p. 137.ISBN978-0-471-97819-0.
  23. ^Ricci A, Mignini F, Tomassoni D, Amenta F (2006). "Dopamine receptor subtypes in the human pulmonary arterial tree".Autonomic and Autacoid Pharmacology.26(4):361–9.doi:10.1111/j.1474-8673.2006.00376.x.PMID16968475.
  24. ^Cavallotti C, Massimo M, Paolo B, Maurizio S, Fiorenzo M (2010). "Dopamine receptor subtypes in the native human heart".Heart and Vessels.25(5):432–7.doi:10.1007/s00380-009-1224-4.hdl:11573/230067.PMID20676967.S2CID36507640.
  25. ^abcdHussain T, Lokhandwala MF (2003). "Renal dopamine receptors and hypertension".Exp. Biol. Med. (Maywood).228(2):134–42.doi:10.1177/153537020322800202.PMID12563019.S2CID10896819.
  26. ^Ricci A, Bronzetti E, Fedele F, Ferrante F, Zaccheo D, Amenta F (1998). "Pharmacological characterization and autoradiographic localization of a putative dopamine D4 receptor in the heart".J Auton Pharmacol.18(2):115–21.doi:10.1046/j.1365-2680.1998.1820115.x.hdl:11573/464054.PMID9730266.
  27. ^Leung PS (2010),"Overview of the Pancreas",The Renin-Angiotensin System: Current Research Progress in The Pancreas,Advances in Experimental Medicine and Biology, vol. 690, Dordrecht: Springer Netherlands, pp.3–12,doi:10.1007/978-90-481-9060-7_1,ISBN978-90-481-9059-1,PMID20700834,retrieved12 April2024
  28. ^Tan SY, Mei Wong JL, Sim YJ, Wong SS, Mohamed Elhassan SA, Tan SH, et al. (January 2019)."Type 1 and 2 diabetes mellitus: A review on current treatment approach and gene therapy as potential intervention".Diabetes & Metabolic Syndrome: Clinical Research & Reviews.13(1):364–372.doi:10.1016/j.dsx.2018.10.008.PMID30641727.
  29. ^Rubí B, Ljubicic S, Pournourmohammadi S, Carobbio S, Armanet M, Bartley C, et al. (November 2005)."Dopamine D2-like Receptors Are Expressed in Pancreatic Beta Cells and Mediate Inhibition of Insulin Secretion".Journal of Biological Chemistry.280(44):36824–36832.doi:10.1074/jbc.M505560200.PMID16129680.
  30. ^Rubí B, Ljubicic S, Pournourmohammadi S, Carobbio S, Armanet M, Bartley C, et al. (November 2005)."Dopamine D2-like Receptors Are Expressed in Pancreatic Beta Cells and Mediate Inhibition of Insulin Secretion".Journal of Biological Chemistry.280(44):36824–36832.doi:10.1074/jbc.M505560200.PMID16129680.
  31. ^Liu M, Ren L, Zhong X, Ding Y, Liu T, Liu Z, et al. (7 April 2020)."D2-Like Receptors Mediate Dopamine-Inhibited Insulin Secretion via Ion Channels in Rat Pancreatic β-Cells".Frontiers in Endocrinology.11:152.doi:10.3389/fendo.2020.00152.ISSN1664-2392.PMC7154177.PMID32318020.
  32. ^Aslanoglou D, Bertera S, Sánchez-Soto M, Benjamin Free R, Lee J, Zong W, et al. (16 February 2021)."Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors".Translational Psychiatry.11(1): 59.doi:10.1038/s41398-020-01171-z.ISSN2158-3188.PMC7884786.PMID33589583.
  33. ^Kaar SJ, Natesan S, McCutcheon R, Howes OD (August 2020)."Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology".Neuropharmacology.172:107704.doi:10.1016/j.neuropharm.2019.107704.PMID31299229.
  34. ^Muench J, Hamer AM (1 March 2010)."Adverse effects of antipsychotic medications".American Family Physician.81(5):617–622.ISSN1532-0650.PMID20187598.
  35. ^Nadal R (September 2001)."Pharmacology of the Atypical Antipsychotic Remoxipride, a Dopamine D 2 Receptor Antagonist".CNS Drug Reviews.7(3):265–282.doi:10.1111/j.1527-3458.2001.tb00199.x.ISSN1080-563X.PMC6741677.PMID11607043.
  36. ^Kane JM, Correll CU (15 September 2010)."Past and Present Progress in the Pharmacologic Treatment of Schizophrenia".The Journal of Clinical Psychiatry.71(9):1115–1124.doi:10.4088/JCP.10r06264yel.ISSN0160-6689.PMC3065240.PMID20923620.
  37. ^Hassanabad MF, Fatehi M (18 January 2019)."Current Views on Dopaminergic Drugs Affecting Glucose Homeostasis".Current Diabetes Reviews.15(2):93–99.doi:10.2174/1573399814666180424123912.PMID29692257.
  38. ^Schneier FR, Liebowitz MR, Abi-Dargham A, Zea-Ponce Y, Lin SH, Laruelle M (2000). "Low dopamine D(2) receptor binding potential in social phobia".Am J Psychiatry.157(3):457–459.doi:10.1176/appi.ajp.157.3.457.PMID10698826.
  39. ^abcKienast T, Heinz A (2006). "Dopamine and the diseased brain".CNS Neurol Disord Drug Targets.5(1):109–31.doi:10.2174/187152706784111560.PMID16613557.
  40. ^Fuxe K, Manger P, Genedani S, Agnati L (2006). "The nigrostriatal DA pathway and Parkinson's disease".Parkinson's Disease and Related Disorders.Journal of Neural Transmission. Supplementa. Vol. 70. pp.71–83.doi:10.1007/978-3-211-45295-0_13.ISBN978-3-211-28927-3.PMID17017512.{{cite book}}:|journal=ignored (help)
  41. ^Mihara K, Kondo T, Suzuki A, Yasui-Furukori N, Ono S, Sano A, et al. (2003). "Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome".Am. J. Med. Genet. B Neuropsychiatr. Genet.117B(1):57–60.doi:10.1002/ajmg.b.10025.PMID12555236.S2CID44866985.
  42. ^Faraone SV, Khan SA (2006). "Candidate gene studies of attention-deficit/hyperactivity disorder".J Clin Psychiatry.67(Suppl 8):13–20.PMID16961425.
  43. ^abHummel M, Unterwald EM (2002)."D1 dopamine receptor: a putative neurochemical and behavioral link to cocaine action".J. Cell. Physiol.191(1):17–27.doi:10.1002/jcp.10078.PMID11920678.S2CID40444893.
  44. ^abGornick MC, Addington A, Shaw P, Bobb AJ, Sharp W, Greenstein D, et al. (2007)."Association of the dopamine receptor D4 (DRD4) gene 7-repeat allele with children with attention-deficit/hyperactivity disorder (ADHD): an update".Am. J. Med. Genet. B Neuropsychiatr. Genet.144B(3):379–82.doi:10.1002/ajmg.b.30460.PMID17171657.S2CID25065281.
  45. ^Schoots O, Van Tol HH (2003). "The human dopamine D4 receptor repeat sequences modulate expression".Pharmacogenomics J.3(6):343–8.doi:10.1038/sj.tpj.6500208.PMID14581929.
  46. ^Berridge KC, Robinson TE (1998)."What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?".Brain Research. Brain Research Reviews.28(3):309–369.doi:10.1016/s0165-0173(98)00019-8.PMID9858756.S2CID11959878.
  47. ^Liggins J, Pihl RO, Benkelfat C, Leyton M (2012)."The dopamine augmenter L-DOPA does not affect positive mood in healthy human volunteers".PLOS ONE.7(1): e28370.Bibcode:2012PLoSO...728370L.doi:10.1371/journal.pone.0028370.ISSN1932-6203.PMC3251561.PMID22238577.
  48. ^Olney JJ, Warlow SM, Naffziger EE, Berridge KC (2018)."Current perspectives on incentive salience and applications to clinical disorders".Current Opinion in Behavioral Sciences.22:59–69.doi:10.1016/j.cobeha.2018.01.007.ISSN2352-1546.PMC5831552.PMID29503841.
  49. ^ab"Drugs and the Brain".National Institute on Drug Abuse.22 March 2022.Retrieved21 August2022.
  50. ^abDi Chiara G, Bassareo V, Fenu S, De Luca MA, Spina L, Cadoni C, et al. (2004). "Dopamine and drug addiction: the nucleus accumbens shell connection".Neuropharmacology.47(Suppl 1):227–41.doi:10.1016/j.neuropharm.2004.06.032.PMID15464140.S2CID25983940.
  51. ^abcPotenza MN (October 2008)."Review. The neurobiology of pathological gambling and drug addiction: an overview and new findings".Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences.363(1507):3181–9.doi:10.1098/rstb.2008.0100.PMC2607329.PMID18640909.
  52. ^Leibenluft E (October 1999). "Gender differences in major depressive disorder and bipolar disorder".CNS Spectrums.4(10):25–33.doi:10.1017/S1092852900012335.PMID18438310.S2CID20594850.
  53. ^Jose PA, Eisner GM, Felder RA (2003). "Regulation of blood pressure by dopamine receptors".Nephron Physiol.95(2):19–27.doi:10.1159/000073676.PMID14610323.S2CID28595227.
  54. ^Lang AE, Obeso JA (May 2004). "Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough".The Lancet. Neurology.3(5):309–16.doi:10.1016/S1474-4422(04)00740-9.PMID15099546.S2CID6551470.
  55. ^Nestler EJ (1 January 2004). "Molecular mechanisms of drug addiction".Neuropharmacology.47(Suppl 1):24–32.doi:10.1016/j.neuropharm.2004.06.031.PMID15464123.S2CID11266116.
  56. ^Scheler G (2004). "Regulation of neuromodulator receptor efficacy--implications for whole-neuron and synaptic plasticity".Prog. Neurobiol.72(6):399–415.arXiv:q-bio/0401039.doi:10.1016/j.pneurobio.2004.03.008.PMID15177784.S2CID9353254.
  57. ^Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, et al. (2000). "Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study".Psychopharmacology.152(2):174–80.doi:10.1007/s002130000532.PMID11057521.S2CID20804595.
  58. ^abcdefghijklmnOlsen CM (December 2011)."Natural rewards, neuroplasticity, and non-drug addictions".Neuropharmacology.61(7):1109–22.doi:10.1016/j.neuropharm.2011.03.010.PMC3139704.PMID21459101.Cross-sensitization is also bidirectional, as a history of amphetamine administration facilitates sexual behavior and enhances the associated increase in NAc DA... As described for food reward, sexual experience can also lead to activation of plasticity-related signaling cascades. The transcription factor delta FosB is increased in the NAc, PFC, dorsal striatum, and VTA following repeated sexual behavior (Wallace et al., 2008; Pitchers et al., 2010b). This natural increase in delta FosB or viral overexpression of delta FosB within the NAc modulates sexual performance, and NAc blockade of delta FosB attenuates this behavior (Hedges et al, 2009; Pitchers et al., 2010b). Further, viral overexpression of delta FosB enhances the conditioned place preference for an environment paired with sexual experience (Hedges et al., 2009).... In some people, there is a transition from "normal" to compulsive engagement in natural rewards (such as food or sex), a condition that some have termed behavioral or non-drug addictions (Holden, 2001; Grant et al., 2006a).... In humans, the role of dopamine signaling in incentive-sensitization processes has recently been highlighted by the observation of a dopamine dysregulation syndrome in some patients taking dopaminergic drugs. This syndrome is characterized by a medication-induced increase in (or compulsive) engagement in non-drug rewards such as gambling, shopping, or sex (Evans et al, 2006; Aiken, 2007; Lader, 2008). "Table 1"
  59. ^Fehr C, Yakushev I, Hohmann N, Buchholz HG, Landvogt C, Deckers H, et al. (April 2008). "Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse".The American Journal of Psychiatry.165(4):507–14.doi:10.1176/appi.ajp.2007.07020352.PMID18316420.
  60. ^Park P (9 August 2007)."Food Addiction: From Drugs to Donuts, Brain Activity May be the Key".
  61. ^Johnson PM, Kenny PJ (May 2010)."Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats".Nature Neuroscience.13(5):635–41.doi:10.1038/nn.2519.PMC2947358.PMID20348917.
  62. ^"Gene Therapy For Addiction: Flooding Brain With 'Pleasure Chemical' Receptors Works On Cocaine, As On Alcohol".18 April 2008.
  63. ^Staley JK, Mash DC (October 1996)."Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities".The Journal of Neuroscience.16(19):6100–6.doi:10.1523/JNEUROSCI.16-19-06100.1996.PMC6579196.PMID8815892.
  64. ^Volkow ND, Wang GJ, Logan J, Alexoff D, Fowler JS, Thanos PK, et al. (14 April 2015)."Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain".Translational Psychiatry.5(4): e549.doi:10.1038/tp.2015.46.ISSN2158-3188.PMC4462609.PMID25871974.
  65. ^Voiculescu M, Ghiță I, Segărceanu A, Fulga I, Coman O (2014)."Molecular and pharmacodynamic interactions between caffeine and dopaminergic system".Journal of Medicine and Life.7(Spec Iss 4):30–38.ISSN1844-122X.PMC4813614.PMID27057246.
  66. ^Ilieva IP, Hook CJ, Farah MJ (January 2015)."Prescription Stimulants' Effects on Healthy Inhibitory Control, Working Memory, and Episodic Memory: A Meta-analysis".J. Cogn. Neurosci.27(6):1069–1089.doi:10.1162/jocn_a_00776.PMID25591060.S2CID15788121.The present meta-analysis was conducted to estimate the magnitude of the effects of methylphenidate and amphetamine on cognitive functions central to academic and occupational functioning, including inhibitory control, working memory, short-term episodic memory, and delayed episodic memory. In addition, we examined the evidence for publication bias. Forty-eight studies (total of 1,409 participants) were included in the analyses. We found evidence for small but significant stimulant enhancement effects on inhibitory control and short-term episodic memory. Small effects on working memory reached significance, based on one of our two analytical approaches. Effects on delayed episodic memory were medium in size. However, because the effects on long-term and working memory were qualified by evidence for publication bias, we conclude that the effect of amphetamine and methylphenidate on the examined facets of healthy cognition is probably modest overall. In some situations, a small advantage may be valuable, although it is also possible that healthy users resort to stimulants to enhance their energy and motivation more than their cognition.... Earlier research has failed to distinguish whether stimulants' effects are small or whether they are nonexistent (Ilieva et al., 2013; Smith & Farah, 2011). The present findings supported generally small effects of amphetamine and methylphenidate on executive function and memory. Specifically, in a set of experiments limited to high-quality designs, we found significant enhancement of several cognitive abilities....

    The results of this meta-analysis cannot address the important issues of individual differences in stimulant effects or the role of motivational enhancement in helping perform academic or occupational tasks. However, they do confirm the reality of cognitive enhancing effects for normal healthy adults in general, while also indicating that these effects are modest in size.
  67. ^abMalenka RC, Nestler EJ, Hyman SE (2009). "Chapter 13: Higher Cognitive Function and Behavioral Control". In Sydor A, Brown RY (eds.).Molecular Neuropharmacology: A Foundation for Clinical Neuroscience(2nd ed.). New York: McGraw-Hill Medical. p. 318.ISBN978-0-07-148127-4.Mild dopaminergic stimulation of the prefrontal cortex enhances working memory....
    Therapeutic (relatively low) doses of psychostimulants, such as methylphenidate and amphetamine, improve performance on working memory tasks both in normal subjects and those with ADHD. Positron emission tomography (PET) demonstrates that methylphenidate decreases regional cerebral blood flow in the doroslateral prefrontal cortex and posterior parietal cortex while improving performance of a spatial working memory task. This suggests that cortical networks that normally process spatial working memory become more efficient in response to the drug.... [It] is now believed that dopamine and norepinephrine, but not serotonin, produce the beneficial effects of stimulants on working memory. At abused (relatively high) doses, stimulants can interfere with working memory and cognitive control... stimulants act not only on working memory function, but also on general levels of arousal and, within the nucleus accumbens, improve the saliency of tasks. Thus, stimulants improve performance on effortful but tedious tasks... through indirect stimulation of dopamine and norepinephrine receptors.
  68. ^abWood S, Sage JR, Shuman T, Anagnostaras SG (January 2014)."Psychostimulants and cognition: a continuum of behavioral and cognitive activation".Pharmacol. Rev.66(1):193–221.doi:10.1124/pr.112.007054.PMC3880463.PMID24344115.
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Dopamine_receptor&oldid=1259553374"